Kalbe Farma Tbk PT (KLBF)

Jakarta
Currency in IDR
1,520
-15(-0.98%)
Delayed Data·

KLBF Financial Summary

Key Ratios

P/E Ratio21.1
Price/Book3.11
Debt / Equity2.11%
Return on Equity13.62%
Dividend Yield2.34%
EBITDA4.83T
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa23,112,654.9926,261,194.5128,933,502.6530,449,134.0832,627,776.11
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa10,074,560.311,105,061.1211,518,600.7511,551,488.9812,711,933.19
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa3,586,492.914,030,862.394,248,218.53,649,483.414,110,223.12
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa2,733,259.863,183,621.313,382,209.772,766,748.043,240,636.63
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa22,564,300.3225,666,635.1627,241,313.0327,057,568.1829,429,727.9
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa3,176,226.393,534,656.094,431,038.463,243,168.544,185,749.49
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa18,276,082.1421,265,877.7922,097,328.223,120,022.0124,590,433.81
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa2,461,988.761,268,017.76-725,101.991,262,873.513,194,774.82
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa4,221,549.822,825,946.281,271,888.672,908,095.714,785,179.04
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-951,215.26-1,056,018.84-1,370,390.19-1,140,786.69-1,247,287.97
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-1,099,712.43-745,176.53-2,405,753.85-2,444,606.88-2,091,905.54
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa2,215,080.561,008,318.38-2,266,478.95-717,348.261,490,873.24
* In Millions of IDR (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 72.97%
Dividend Yield
2.34%
Industry Median 6.63%
Annualised payout
36.00
Paid annually
5-Years Growth
+6.72%
Growth Streak

Analyst Ratings

12 Buy
2 Hold
1 Sell
Ratings:
15 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1,660
(+9.23% Upside)

Earnings

Latest Release
Apr 30, 2025
EPS / Forecast
20.60 / 18.63
Revenue / Forecast
8.845T / --
EPS Revisions
Last 90 days

FAQ

What were Kalbe Farma's earnings for the latest quarter?

The Kalbe Farma EPS (TTM) is 72.97. Kalbe Farma reported sales of 8,845,368.16, net income of 1,076,772.40, and EPS of 20.60 for the latest quarter.

What was Kalbe Farma's net income for the latest quarter?

Kalbe Farma's net income for the latest quarter was 1,076,772.40.

How did Kalbe Farma's performance compare year-over-year in the latest quarter?

The company's revenue moved from 8,389,013.38 in the previous quarter to 8,845,368.16 in the latest quarter, and net income moved from 862,257.53 to 1,076,772.40 compared to the previous quarter.

What is Kalbe Farma's net profit margin on a TTM basis?

Kalbe Farma's trailing twelve months (TTM) net profit margin is 9.93%.

How does Kalbe Farma's debt to equity ratio compare to industry standards?

Kalbe Farma's total debt-to-equity ratio is 2.11%.

What is Kalbe Farma's return on investment on a TTM basis?

Kalbe Farma's trailing twelve months (TTM) return on investment (ROI) is 13.62%.

Did Kalbe Farma gain or lose cash last quarter?

In the latest quarter, Kalbe Farma's net change in cash was -180,460.08 million.

What were Kalbe Farma's total assets and liabilities in the latest quarter?

As of the latest quarter, Kalbe Farma reported total assets of 30,579,056.12 million and total liabilities of 4,534,519.66 million.

How has Kalbe Farma's total revenue grown this year?

Kalbe Farma's total revenue was 8,389,013.38 in the previous quarter and 8,845,368.16 in the latest quarter.

What is Kalbe Farma's gross margin on a TTM basis?

Kalbe Farma's trailing twelve months (TTM) gross margin is 39.46%.

What was Kalbe Farma's revenue per share for the latest quarter?

Kalbe Farma's revenue per share for the latest quarter was 1,447.46.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.